{"id":600076,"date":"2022-05-16T14:14:01","date_gmt":"2022-05-16T14:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=600076"},"modified":"2022-05-16T14:14:01","modified_gmt":"2022-05-16T14:14:01","slug":"cancer-biomarkers-market-worth-282-billion-by-2026-global-trends-share-and-leading-key-players","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cancer-biomarkers-market-worth-282-billion-by-2026-global-trends-share-and-leading-key-players_600076.html","title":{"rendered":"Cancer Biomarkers Market worth $28.2 billion by 2026 – Global Trends, Share and Leading Key Players"},"content":{"rendered":"
\n
\"Cancer<\/a><\/div>\n
\n
Some key players in the cancer biomarkers market are QIAGEN N.V. (Netherlands), ; Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioM\u00e9rieux SA (US), Becton, Dickinson and Company (US).<\/div>\n<\/div>\n<\/div>\n
North America is the largest regional market for cancer biomarkers market<\/div>\n

According to the new market research report “Cancer Biomarkers Market<\/a> by Type (Protein, Genetic), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnostics, R&D, Prognostics), Region – Global Forecast to 2026″,<\/strong> published by MarketsandMarkets™, the global market is projected to reach USD 28.2 billion by 2026 from USD 12.4 billion in 2021, at a CAGR of 17.7%.<\/p>\n

Browse in-depth TOC on <\/em>“Cancer Biomarkers Market”<\/strong>
<\/strong>229 – Tables
50 – Figures
287 – Pages<\/p>\n

Download PDF Brochure: <\/strong>https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=202<\/a>
<\/a><\/p>\n

The Growing preference for wireless connectivity among healthcare providers, Increasing incidence of cancer worldwide, increasing use of cancer biomarkers in drug discovery & development and increasing R&D on cancer biomarkers are among the other factors. Emerging economies such as India and Japan are providing lucrative opportunities for the players operating in the market.<\/p>\n

The protein biomarkers segment accounted for the largest share of the cancer biomarkers market, by biomarker type segment, in 2020<\/strong><\/p>\n

Based on biomarkers type, the market is segmented into protein biomarkers, genetic biomarkers and other cancer biomarkers. The protein biomarkers segment accounted for the largest share of the cancer biomarker market, mainly due to rising technological advancements In the development of cancer biomarkers and increasing R&D on cancer biomarkers.<\/p>\n

Lung cancer segment to register the highest growth rate during the forecast period<\/strong><\/p>\n

The cancer biomarker market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, thyroid cancer, bladder cancer, non-hodgkins lymphoma, kidney cancer and other cancer types based on cancer type. In 2020, the breast cancer segment accounted for the largest share of the cancer biomarkers market. The large share of this segment can mainly be attributed to the increasing incidence of cancer worldwide and increasing use of cancer biomarkers in drug discovery & development.<\/p>\n

Request Sample Pages: <\/strong>https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=202<\/a>
<\/a><\/p>\n

The omics technology accounted for the largest share of the cancer biomarkers market, by profiling technology segment, in 2020<\/strong><\/p>\n

Based on profiling technology, the market has been segmented into omics technologies, imaging technologies, immunoassay, bioinformatics, and cytogenetics. In 2020, the omics technology segment accounted for the largest share of the cancer biomarker market, mainly due to the increasing use of cancer biomarkers in drug discovery & development and increasing R&D on cancer biomarkers.<\/p>\n

The diagnostics segment accounted for the largest share of the cancer biomarkers market, by application segment, in 2020<\/strong><\/p>\n

Based on application, the cancer biomarker market has been segmented into diagnostics, research & development, prognostics, risk assessment, and other applications. In 2020, the diagnostics segment accounted for the largest share of the cancer biomarker market, mainly due to the increasing incidence of cancer worldwide and increasing use of cancer biomarkers in drug discovery & development.<\/p>\n

The global cancer biomarker market is segmented into five major regions – North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest regional market for market in 2020. The large share of North America in this market can be attributed to the rising technological advancements In the development of cancer biomarkers, increasing incidence of cancer worldwide, and increasing use of cancer biomarkers in drug discovery & development.<\/p>\n

The major players operating in this Cancer Biomarkers Market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), ; Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Hologic, Inc. (US), Quest Diagnostics (US), Centogene N.V. (Germany), PerkinElmer, Inc.; (US), Siemens Healthineers (Germany), Exact Sciences (US), R&D Systems, Inc. (US), BioVision, Inc. (US), Olink (Sweden), Asuragen, Inc. (US), Meso Scale Diagnostics, LLC (US), Invivoscribe, Inc. (US), Seegene Technologies, Inc. (South Korea).<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Marketsandmarkets pvt ltd<\/a>
Contact Person:<\/strong> Mr. Aashish Mehra
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 18886006441
Address:<\/strong>630 Dundee Road Suite 430
City:<\/strong> Northbrook
State:<\/strong> IL 60062
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.marketsandmarkets.com\/Market-Reports\/oncology-biomarkers-202.html<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Some key players in the cancer biomarkers market are QIAGEN N.V. (Netherlands), ; Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioM\u00e9rieux SA (US), Becton, Dickinson and Company (US). North America is the largest regional market for cancer … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404,416],"tags":[],"class_list":["post-600076","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/600076","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=600076"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/600076\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=600076"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=600076"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=600076"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}